激活cGAS/STING以驱动抗癌免疫的免疫代谢途径
Francisca Borges1, Abhishek D Garg1
1Cell Stress and Immunity (CSI) Laboratory, Department for Cellular and Molecular Medicine (CMM), KU Leuven, Leuven, Belgium.
Cancer research
|August 15, 2024
概括
血清素缺乏会触发cGAS/STING通路,增强抗瘤免疫力. 这种代谢策略在癌症治疗方面表现有前途,在与PD1阻断相结合时,增强免疫反应和改善患者存活率.
科学领域:
- 免疫学 免疫学 免疫学
- 代谢途径 代谢途径
- 癌症生物学 癌症生物学
背景情况:
- 这种cGAS/STING通路对抗癌症的天生的免疫反应至关重要.
- 氨酸是一种必需的氨基酸,影响瘤生长和免疫监测.
- 线粒体DNA (mtDNA) 的释放可以激活免疫信号通路.
研究的目的:
- 为了研究血清素剥夺对cGAS/STING通路的影响.
- 探索血清素剥夺作为抗癌疗法的潜力.
- 为了评估血清素剥夺与免疫检查点抑制剂的组合.
主要方法:
- 在细胞和小鼠模型中诱导血清缺乏.
- 测量线粒体功能障碍和mtDNA释放.
- 评估免疫细胞透和I型干扰素 (IFN) 反应.
- 在结肠直肠癌中分析血清缩特征的临床数据.
主要成果:
- 血清素缺乏导致线粒体功能障碍和mtDNA释放,激活cGAS/STING通路.
- 这种激活会诱导I型IFN反应,并增强抗瘤免疫力,包括CD4+/CD8+T细胞透.
- 结直肠癌患者的低血清丰富与免疫激活和更好的生存相关.
- 将血清素剥夺与PD1阻断相结合,可显著降低瘤体积,并在小鼠中建立长期免疫力.
结论:
- 血清缺乏是一种可行的策略,可以激活cGAS/STING通路并增强抗瘤免疫力.
- 这种方法提高了免疫检查点阻塞疗法的有效性.
- 氨酸代谢调节为改善癌症治疗结果提供了一个有希望的途径.
相关概念视频
Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
Cytotoxic T Cells-mediated Immune Response
861
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
861
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Antigen Processing Pathways
962
MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...
MHC Class I: Presenting Endogenous...
962
Cancer Vaccines
347
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
347
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K


